CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials: A Guidance Document Potential protective mechanisms of green tea polyphenol EGCG against COVID-19 Causes of Mortality After Percutaneous Coronary Intervention: Insights From the VA Clinical Assessment, Reporting, and Tracking Program Overall and Cause-Specific Mortality in Randomized Clinical Trials Comparing Percutaneous Interventions With Coronary Bypass Surgery: A Meta-analysis The Future of Cardiovascular Computed Tomography Advanced Analytics and Clinical Insights Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Limitations of Repeat Revascularization as an Outcome Measure Pediatric Post–Cardiac Arrest Care: A Scientific Statement From the American Heart Association

Editorial2018 Jan 6;391(10115):3-4.

JOURNAL:Lancet. Article Link

Last nail in the coffin for PCI in stable angina?

Brown DL, Redberg RF. Keywords: comment; stable angina; PCI

ABSTRACT


Interventional cardiology began in Switzerland in 1977, when Andreas Gruentzig performed the first successful percutaneous transluminal coronary angioplasty (PTCA) on a 38-year-old man with angina and a focal proximal stenosis of the left anterior descending coronary artery. Despite numerous subsequent randomised trials and meta-analyses of these trials, which have shown no reduction in death or myocardial infarction,1 the use of percutaneous coronary intervention (PCI) has grown exponentially. Some of this growth was driven by data from clinical trials suggesting that PCI was more effective in relieving angina than medical therapy alone.